Compare Dyne Therapeutics Inc. Common Stock (DYN) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs S&P500 ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while S&P500 ETF trades at $767.04 (market cap $821.11B). The key difference: S&P500 ETF is far larger — about 287.1× Dyne Therapeutics Inc. Common Stock's market cap, and S&P500 ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and S&P500 ETF for 206 Days on average.
| DYN | SPY | |
|---|---|---|
Market Cap | $2.86B | $821.11B |
Volume | 3,341,579 | 25,825,560 |
Sector | Health | — |
52-Week High | $26.78 | $779.14 |
52-Week Low | $14.60 | $631.99 |
Typical Hold Time | 0 Days | 206 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SPY (SPDR S&P 500 ETF Trust) trades at $778.05, showing minimal daily movement with a slight decline of -0.02 (-0.0%). Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains its position as the primary S&P 500 tracking fund with upcoming dividend distribution scheduled for October 2026.
The ETF's outlook remains tied to broader market performance with Wall Street monitoring earnings growth projections. Key risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated market valuations. Current technical strength suggests near-term stability, but macroeconomic factors could drive volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
